106  Ru radiolabelling of the antitumour complex [(η6-fluorene)Ru(en)Cl]PF6

James D. Hoeschele; Abraha Habtemariam; Jeanette Muir; Peter J. Sadler

doi:10.1039/B706246J

skip RSC | ChemSpider | Feedback

Home > Journals > Dalton Transactions > 106Ru radiolabelling of...

Authors & Referees | Librarians

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Dalton Transactions

Issue 43, 2007

More about this Journal
Editorial Board
Submit an Article

Follow Journal | |

Journal Home | RSC Journals

Paper

Previous Article | Next Article

¹⁰⁶ Ru radiolabelling of the antitumour complex [(η⁶-fluorene)Ru(en)Cl]PF₆

James D. Hoeschele , Abraha Habtemariam , Jeanette Muir and Peter J. Sadler

Dalton Trans., 2007, 4974-4979

DOI: 10.1039/B706246J
Received 25 Apr 2007, Accepted 23 May 2007
First published on the web 04 Oct 2007
This article is part of the collection: Dalton Discussion 10: Applications of metals in medicine and healthcare

Please wait while Download options loads

Request Permissions

Abstract
Cited by
Related Content

The organometallic half-sandwich Ru^II arene anticancer complex [(η⁶-fluorene)Ru(en)Cl]PF₆ (1) has been synthesized in high yield and purity on a micromole scale with incorporation of the β-emitting radioisotope ¹⁰⁶Ru (half-life = 1.01 y) using a refined procedure involving conversion of RuCl₃ into [(η⁶-fluorene)RuCl₂]₂, and then [(η⁶-fluorene)Ru(CH₃CN)₂Cl]PF₆ as intermediates. Distribution studies 0.25 h post i.v. injection of ¹⁰⁶Ru-1 at a dose of 25 mg 1 kg⁻¹ show that ¹⁰⁶Ru is well distributed throughout the tissues of a rat. This appears to be the first report of the radiolabelling of a potential ruthenium antitumour agent for distribution/biological studies.

Terms & Conditions|Privacy |Accessibility|ACAP Enabled

Dalton Transactions

¹⁰⁶ Ru radiolabelling of the antitumour complex [(η⁶-fluorene)Ru(en)Cl]PF₆

Log in (Free Access)

Log in (Subscriber Access)

Articles By